Federated Hermes’s Enliven Therapeutics ELVN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $323K | Sell |
16,098
-52,953
| -77% | -$1.06M | ﹤0.01% | 1426 |
|
|
2025
Q1 | $1.36M | Sell |
69,051
-48,501
| -41% | -$954K | ﹤0.01% | 1031 |
|
|
2024
Q4 | $2.64M | Buy |
+117,552
| New | +$2.64M | 0.01% | 871 |
|
|
2023
Q2 | – | Sell |
-243
| Closed | -$5.32K | – | 2136 |
|
|
2023
Q1 | $5.32K | Sell |
243
-17
| -7% | -$372 | ﹤0.01% | 1928 |
|
|
2022
Q4 | $4.25K | Sell |
260
-134
| -34% | -$2.19K | ﹤0.01% | 1941 |
|
|
2022
Q3 | $4K | Sell |
394
-542
| -58% | -$5.5K | ﹤0.01% | 1907 |
|
|
2022
Q2 | $5K | Sell |
936
-24
| -3% | -$128 | ﹤0.01% | 1895 |
|
|
2022
Q1 | $7K | Buy |
960
+266
| +38% | +$1.94K | ﹤0.01% | 1916 |
|
|
2021
Q4 | $6K | Buy |
694
+275
| +66% | +$2.38K | ﹤0.01% | 1975 |
|
|
2021
Q3 | $7K | Buy |
+419
| New | +$7K | ﹤0.01% | 2017 |
|